Skip to content

Impact of ICU on the Quality of Life in Cancer Patients

Impact of ICU on the Quality of Life and Oncological Care of Patients With Solid Tumors

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04310033
Acronym
QdV-ONCOREA
Enrollment
60
Registered
2020-03-17
Start date
2020-02-24
Completion date
2021-07-13
Last updated
2021-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor, Adult

Keywords

Quality of life, Oncological care, intensive care unit, solid tumor

Brief summary

This is an observational, prospective, monocentric, case-control study. Investigators aim to compare the quality of life and oncological treatment strategy in cancer patients admitted or not in ICU.

Detailed description

Inclusion of cancer patients (cases) at discharge of surgical, cardiovascular and thoracic and medical ICU of the Grenoble Alpes University Hospital. Cases will be matched with cancer patients identified in oncologist's consultation. Inclusion of controls from oncologist consultations (2 controls for 1 case) For cases and controls, medical data will be collected at inclusion, 3 and 6 months.

Interventions

OTHERQuestionnaires

Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \> 18 ans * Non-opposition of the patient or relatives * Lung, head and neck or colorectal cancer * Non scheduled ICU admission * At least 24 hours of ICU stay * Alive at ICU discharge * Able to answer by phone to quality of life questionary

Exclusion criteria

* Unable to answer by phone to quality of life questionary * Patient participating in another clinical study that could interfere with the results of the study

Design outcomes

Primary

MeasureTime frameDescription
quality of life questionary 36-item short form survey instrument (36-SF)3 monthsscore of 0 (poor quality of life) to 100 (very good quality of life)

Secondary

MeasureTime frameDescription
intensity of antitumoral treatment compared to standard treatment3 monthsstandard treatment vs adaptated treatment vs palliative care standard treatment was defined by the treatment recommended in the ESMO guidelines for each cancer (lung, colorectal, and head and neck cancer)
quality of life questionary 36-item short form survey instrument (36-SF)6 monthsscore of 0 (poor quality of life) to 100 (very good quality of life)
ECOG - Performance status3 months and 6 monthsFrom 0 (fully active) to 5 (dead)
Activities of Daily Living6 monthsFrom 0 (dependent ) to 6 (autonomous)
Hospital Anxiety and Depression Scale3 months and 6 monthsAnxiety scale from 0 (no anxiety) to 21 (anxiety) Depression Scale from 0 (no depression) to 21 (depression)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026